Premium
Sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology
Author(s) -
Seferović Petar M.,
Fragasso Gabriele,
Petrie Mark,
Mullens Wilfried,
Ferrari Roberto,
Thum Thomas,
Bauersachs Johann,
Anker Stefan D.,
Ray Robin,
Çavuşoğlu Yuksel,
Polovina Marija,
Metra Marco,
Ambrosio Giuseppe,
Prasad Krishna,
Seferović Jelena,
Jhund Pardeep S.,
Dattilo Giuseppe,
Čelutkiene Jelena,
Piepoli Massimo,
Moura Brenda,
Chioncel Ovidiu,
Ben Gal Tuvia,
Heymans Stefan,
Boer Rudolf A.,
Jaarsma Tiny,
Hill Loreena,
Lopatin Yuri,
Lyon Alexander R.,
Ponikowski Piotr,
Lainščak Mitja,
Jankowska Ewa,
Mueller Christian,
Cosentino Francesco,
Lund Lars,
Filippatos Gerasimos S.,
Ruschitzka Frank,
Coats Andrew J.S.,
Rosano Giuseppe M.C.
Publication year - 2020
Publication title -
european journal of heart failure
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.149
H-Index - 133
eISSN - 1879-0844
pISSN - 1388-9842
DOI - 10.1002/ejhf.1954
Subject(s) - dapagliflozin , empagliflozin , medicine , canagliflozin , heart failure , ejection fraction , cardiology , benzhydryl compounds , diabetes mellitus , clinical trial , type 2 diabetes , endocrinology , chemistry , organic chemistry , bisphenol a , epoxy
Heart failure (HF) is common and associated with a poor prognosis, despite advances in treatment. Over the last decade cardiovascular outcome trials with sodium–glucose co‐transporter 2 (SGLT2) inhibitors in patients with type 2 diabetes mellitus have demonstrated beneficial effects for three SGLT2 inhibitors (empagliflozin, canagliflozin and dapagliflozin) in reducing hospitalisations for HF. More recently, dapagliflozin reduced the risk of worsening HF or death from cardiovascular causes in patients with chronic HF with reduced left ventricular ejection fraction, with or without type 2 diabetes mellitus. A number of additional trials in HF patients with reduced and/or preserved left ventricular ejection fraction are ongoing and/or about to be reported. The present position paper summarises recent clinical trial evidence and discusses the role of SGLT2 inhibitors in the treatment of HF, pending the results of ongoing trials in different populations of patients with HF.